% | $
Quotes you view appear here for quick access.

Zalicus AŞ Message Board

  • scistats scistats Jun 13, 2013 6:46 PM Flag

    DR. CORRIGAN: PRIALT patent expires in 2016. Time for Prialt 2.0, A.K.A. "Z160" NO SIDE EFFECTS/INFUSION

    End-user sales of PRIALT in the U.S. were approximately $20 million and $18 million in 2009 and 2008, respectively.

    Mr. Seamus Mulligan, Chairman and Chief Executive of Azur Pharma, stated 'We are pleased to add PRIALT, an important therapeutic for the management of severe chronic pain, to our portfolio. We look forward to welcoming the PRIALT team to our organisation and to their continued support for this product. We believe PRIALT will grow with continued investment in the brand. The patents covering PRIALT run through December 2016.

    Sentiment: Strong Buy